{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinoma+%28HNSCC%29&page=50",
    "query": {
      "condition": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "page": 50
    },
    "page_size": 10
  },
  "pagination": {
    "page": 50,
    "page_size": 10,
    "total_count": 1195,
    "total_pages": 120,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinoma+%28HNSCC%29&page=51&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinoma+%28HNSCC%29&page=49&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T17:32:55.466Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05233436",
      "title": "PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Gastric Cancer",
        "Gastroesophageal Junction Cancer",
        "Urothelial Cancer",
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinomas"
      ],
      "interventions": [
        {
          "name": "PF-07265028",
          "type": "DRUG"
        },
        {
          "name": "Sasanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 21,
      "start_date": "2022-02-24",
      "completion_date": "2023-10-16",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05233436"
    },
    {
      "nct_id": "NCT06682793",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "Non-Small Cell Lung",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Cancer",
        "Colon Cancer",
        "Rectal Cancer",
        "Lung Cancer",
        "CRC",
        "Head and Neck Squamous Cell Cancer",
        "HNSCC",
        "Renal Cell Carcinoma",
        "RCC",
        "Kidney Cancer",
        "Triple Negative Breast Cancer",
        "TNBC",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "A2B395",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT CDx with HLA-LOH assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2025-05-22",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06682793"
    },
    {
      "nct_id": "NCT04811027",
      "title": "Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HNSCC"
      ],
      "interventions": [
        {
          "name": "eftilagimod alpha",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immutep S.A.S.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2021-08-27",
      "completion_date": "2025-11-05",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04811027"
    },
    {
      "nct_id": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "NKTR-262",
          "type": "DRUG"
        },
        {
          "name": "bempegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-03-15",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435640"
    },
    {
      "nct_id": "NCT00388024",
      "title": "PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Carcinoma of Unknown Primary",
        "Head and Neck Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2006-02",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00388024"
    },
    {
      "nct_id": "NCT01540682",
      "title": "MLN8237 in Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "MLN8237",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540682"
    },
    {
      "nct_id": "NCT03735680",
      "title": "A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Cancer",
        "Prostate Cancer",
        "Ovarian Cancer",
        "Urothelial Carcinoma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ONM-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoNano Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2019-08-09",
      "completion_date": "2021-11-18",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03735680"
    },
    {
      "nct_id": "NCT02013050",
      "title": "A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "SGX942",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soligenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2013-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013050"
    },
    {
      "nct_id": "NCT01104922",
      "title": "Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic radiosurgery",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "David A. Clump, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2007-12-26",
      "completion_date": "2018-07-26",
      "has_results": true,
      "last_update_posted_date": "2022-02-14",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01104922"
    },
    {
      "nct_id": "NCT06082167",
      "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        },
        {
          "name": "Zanzalintinib-matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-06-07",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-10-16T17:32:55.466Z",
      "location_count": 15,
      "location_summary": "Fullerton, California • Orange City, Florida • Tampa, Florida + 12 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06082167"
    }
  ]
}